Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Debt to Equity (2016 - 2017)

Corcept Therapeutics (CORT) has disclosed Debt to Equity for 6 consecutive years, with $0.07 as the latest value for Q2 2017.

  • Quarterly Debt to Equity fell 92.05% to $0.07 in Q2 2017 from the year-ago period, while the trailing twelve-month figure was $0.07 through Jun 2017, down 92.05% year-over-year, with the annual reading at $0.35 for FY2016, 76.16% down from the prior year.
  • Debt to Equity hit $0.07 in Q2 2017 for Corcept Therapeutics, down from $0.2 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $10.15 in Q2 2014 to a low of -$26.31 in Q3 2014.
  • Historically, Debt to Equity has averaged -$0.29 across 5 years, with a median of $1.0 in 2013.
  • Biggest YoY gain for Debt to Equity was 1109.01% in 2014; the steepest drop was 2437.21% in 2014.
  • Year by year, Debt to Equity stood at $1.67 in 2013, then plummeted by 699.5% to -$10.0 in 2014, then skyrocketed by 114.86% to $1.49 in 2015, then plummeted by 76.16% to $0.35 in 2016, then tumbled by 80.49% to $0.07 in 2017.
  • Business Quant data shows Debt to Equity for CORT at $0.07 in Q2 2017, $0.2 in Q1 2017, and $0.35 in Q4 2016.